Neurotrophic Keratopathy Market Size in the 7MM was ~USD 870 Million in 2024, it is expected to grow significantly by 2034, estimates DelveInsight

Neurotrophic Keratopathy Market Size in the 7MM was ~USD 870 Million in 2024, it is expected to grow significantly by 2034, estimates DelveInsight

Analysis indicates that the Neurotrophic Keratopathy market size in the 7 major markets (7MM) was valued at approximately USD 870 million in 2024 and is anticipated to increase significantly during the forecast period from 2025 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Neurotrophic Keratopathy landscape.

The neurotrophic keratopathy market is projected to grow steadily across the 7MM, driven by increasing disease prevalence, improved diagnosis rates, and the development of emerging regenerative therapies. According to DelveInsight, approximately 140 thousand prevalent cases of neurotrophic keratitis were reported across the 7MM in 2024, with the United States accounting for nearly 67 thousand cases. The increasing burden of the disease, coupled with growing awareness and advancements in therapeutic approaches, is expected to support market expansion through 2034. 

Dompé Farmaceutici and BRIM Biotechnology are among the major companies advancing therapies in the neurotrophic keratopathy market. OXERVATE (cenegermin-bkbj), developed by Dompé Farmaceutici, remains the first FDA-approved treatment for neurotrophic keratitis and continues to play a major role in the treatment landscape. Emerging therapies such as BRM424 are expected to further transform the market by targeting corneal regeneration and nerve repair mechanisms. 

In 2024, the United States accounted for the highest market size for neurotrophic keratitis, representing approximately 98% of the total market size in the 7MM. The US market alone was valued at nearly USD 850 million and is expected to rise significantly during the forecast period. Within the EU4 and the UK, France accounted for the largest market share at nearly 30%, while Germany represented around 10% of the regional market share. Japan also contributed significantly, with approximately 12,350 prevalent cases reported in 2024. 

In 2024, the prevalence of neurotrophic keratitis was notably higher among females in several regions. In Germany, approximately 3,650 prevalent cases were reported among females compared to nearly 2,400 among males. Similarly, in the United States, females accounted for nearly 20 thousand diagnosed prevalent cases, while males represented approximately 13,500 cases. These trends are expected to continue through 2034. 

DelveInsight’s report “Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of the Neurotrophic Keratopathy landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand prevalence, diagnosis patterns, severity-specific burden, and patient demographics across major regions.

Additionally, it examines Neurotrophic Keratopathy market dynamics, offering a thorough assessment of current and emerging market trends, treatment practices, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives. 

To know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario, and epidemiology trends, click here; Neurotrophic Keratopathy Market Forecast.

Some of the key facts of the Neurotrophic Keratopathy Market Report:

• Key Neurotrophic Keratopathy Companies: Dompé Farmaceutici, BRIM Biotechnology, RegeneRx Biopharmaceuticals, RECORDATI, Oyster Point Pharma, Oculis, Claris Biotherapeutics, and others

• Key Neurotrophic Keratopathy Therapies: OXERVATE (cenegermin-bkbj), BRM424, RGN-259 (Tß4), OC-01 (varenicline/Chantix), and others

• The Neurotrophic Keratopathy epidemiology based on gender analyzed that females account for a higher diagnosed prevalent population in several regions

• The Neurotrophic Keratopathy market is expected to expand significantly due to increasing awareness, better diagnosis, and regenerative therapeutic advancements

• Emerging therapies are focused on corneal healing, limbal stem cell regeneration, and restoration of corneal nerve function 

Neurotrophic Keratopathy Overview

Neurotrophic Keratopathy, also known as neurotrophic keratitis, is a rare degenerative corneal disease caused by impaired corneal innervation. The condition leads to reduced or absent corneal sensation, resulting in epithelial breakdown, delayed healing, corneal ulceration, stromal melting, and in severe cases, perforation and vision loss. The disease is associated with damage to the trigeminal nerve and may arise from infections, systemic diseases, surgeries, or long-term ocular surface disorders. Early diagnosis and severity-based treatment are essential to prevent disease progression and preserve vision. 

Get a Free sample for the Neurotrophic Keratopathy Market Report:

Neurotrophic Keratopathy Market Report

Key Trends in Neurotrophic Keratopathy Therapeutics Market:

• Growing adoption of regenerative therapies and nerve growth factor-based treatments: Therapies such as OXERVATE and emerging regenerative peptides are reshaping the treatment landscape by directly targeting corneal healing and nerve repair.

• Emergence of limbal stem cell regeneration approaches: Novel therapies like BRM424 are focused on stimulating limbal stem cell proliferation and differentiation to restore corneal integrity.

• Increasing focus on early diagnosis and advanced imaging: Technologies including in vivo confocal microscopy and high-resolution corneal imaging are improving disease detection and treatment monitoring.

• Expansion of research into targeted biologics and neuroprotective therapies: Companies are developing innovative therapeutic strategies aimed at preventing disease progression and improving long-term visual outcomes.

• Rising awareness and aging population driving disease burden: Improved awareness among ophthalmologists and increasing prevalence in elderly populations are expected to support market growth. 

Neurotrophic Keratopathy Epidemiology

• In 2024, around 60,300 individuals across the EU4 and the UK were estimated to be living with neurotrophic keratitis, underscoring a considerable regional disease burden and emphasizing the increasing demand for timely diagnosis, advanced treatment approaches, and targeted interventions to reduce the risk of long-term corneal complications.

• Among the EU4 and the UK, the UK reported the highest number of diagnosed prevalent neurotrophic keratitis cases, with nearly 8,500 cases in 2024, followed by Germany with around 6,000 cases. In contrast, Spain recorded the lowest diagnosed patient population, with approximately 3,400 cases.

• In the United States, diagnosed prevalent cases of neurotrophic keratitis in 2024 demonstrated a notable gender imbalance, with females accounting for nearly 20,000 cases compared to approximately 13,500 cases among males, indicating a significantly higher disease burden in women.

• In Japan, the number of prevalent neurotrophic keratitis cases was estimated at approximately 12,350 in 2024 and is projected to increase further through 2034, pointing toward a steadily rising disease burden in the country.

Neurotrophic Keratopathy Epidemiology Segmentation:

The Neurotrophic Keratopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Neurotrophic Keratopathy

• Total Diagnosed Prevalent Cases of Neurotrophic Keratopathy

• Gender-Specific Diagnosed Prevalent Cases of Neurotrophic Keratopathy

• Severity-Specific Diagnosed Prevalent Cases of Neurotrophic Keratopathy 

Recent Development in the Neurotrophic Keratopathy Treatment Landscape:

• In December 2022, the US FDA granted Orphan Drug Designation (ODD) to BRM424 by BRIM Biotechnology for the treatment of neurotrophic keratitis.

• In April 2023, BRIM Biotechnology submitted an Investigational New Drug (IND) application for BRM424 Phase II clinical trials in neurotrophic keratitis.

• In September 2023, BRIM Biotechnology raised approximately USD 45.8 million to support pipeline development, including Phase II enrollment of BRM424 for neurotrophic keratitis.

• In July 2020, Dompé Farmaceutici partnered with Tanner Pharma Group as the exclusive distributor of OXERVATE in select countries.

• In August 2018, the US FDA approved OXERVATE (cenegermin) for the treatment of neurotrophic keratitis. 

Neurotrophic Keratopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the uptake rate of recently launched and upcoming therapies in the Neurotrophic Keratopathy market. The analysis covers patient uptake, sales performance, and therapeutic adoption trends.

The report also covers Neurotrophic Keratopathy pipeline development activities and provides insights into therapeutic candidates in different stages of development. It analyzes recent collaborations, acquisitions, licensing activities, and regulatory developments associated with emerging therapies. 

Neurotrophic Keratopathy Therapies and Key Companies

• OXERVATE (cenegermin-bkbj): Dompé Farmaceutici

• BRM424: BRIM Biotechnology

• RGN-259 (Tß4): RegeneRx Biopharmaceuticals/ReGenTree

• OC-01 (varenicline/Chantix): Oyster Point Pharma

• Additional pipeline therapies under development by Oculis, RECORDATI, and Claris Biotherapeutics 

Neurotrophic Keratopathy Market Drivers

• Increasing prevalence and improved diagnosis rates

• Advancements in regenerative and neurotrophic therapies

• Growing awareness among healthcare professionals

• Rising aging population susceptible to ocular surface disorders

• Expanding R&D investments and orphan drug designations

Neurotrophic Keratopathy Market Barriers

• Limited availability of approved therapies

• High treatment costs and reimbursement challenges

• Delayed diagnosis due to overlapping ocular symptoms

• Complex clinical management and monitoring requirements

• Lack of standardized treatment guidelines in some regions

Scope of the Neurotrophic Keratopathy Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Neurotrophic Keratopathy Companies: Dompé Farmaceutici, BRIM Biotechnology, RegeneRx Biopharmaceuticals, RECORDATI, Oyster Point Pharma, Oculis, Claris Biotherapeutics, and others

• Key Neurotrophic Keratopathy Therapies: OXERVATE, BRM424, RGN-259, OC-01, and others

• Neurotrophic Keratopathy Therapeutic Assessment: Current marketed and emerging therapies

• Neurotrophic Keratopathy Market Dynamics: Market drivers and barriers

• Neurotrophic Keratopathy Competitive Intelligence Analysis: SWOT analysis, market entry strategies, reimbursement scenario, and analyst insights 

Discover more about therapies set to grab major Neurotrophic Keratopathy market share @ Neurotrophic Keratopathy Treatment Landscape

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve business performance. It also offers healthcare consulting services to accelerate business growth and overcome market challenges with a practical approach.